Benefits
Prescription enzyme therapy in people with pancreatic insufficiency (not a supplement finding)
Amylase is one of three enzymes in pancreatic enzyme replacement therapy (PERT), a prescription treatment given to people diagnosed with cystic fibrosis, chronic pancreatitis, or pancreatic cancer. The research cited here was done in those patient groups, and its main measured outcomes were fat and nutrient absorption rather than carbohydrate digestion. This is drug therapy for a diagnosed condition, and it does not show that an over the counter amylase supplement does anything for a healthy person's digestion.
Post-meal fullness after starchy meals (not shown in the cited studies)
This is a common marketing claim for digestive enzyme blends, but none of the studies cited on this page tested an enzyme supplement against a placebo for fullness, bloating, or gas after starchy meals. The one citation that involves people with ongoing indigestion (functional dyspepsia overlapping with IBS) simply compared tissue samples between groups and gave nobody a supplement. Any effect on post-meal comfort in healthy people remains untested here.
Maltodextrin and dextrin breakdown for sports nutrition (theory only)
No study cited on this page involved athletes, exercise, or sports drinks. Amylase does break down maltodextrin and dextrins, and the laboratory work cited here (a simulated digestion experiment on bread and pasta, with no human volunteers) shows how the enzyme acts on starch. Whether taking extra amylase changes how an athlete feels or performs during high carbohydrate fueling has not been tested, and 'subclinical amylase deficiency' is not a condition any of these studies measured.
Blood sugar response to starchy meals (not measured in the cited studies)
None of the studies cited on this page measured blood sugar, insulin, or glycemic response after a meal, so there is no support here for the idea that amylase supplements smooth out blood sugar spikes. Worth knowing the direction of the biology: amylase speeds starch breakdown, which is the opposite of what acarbose (a prescription diabetes drug) does by blocking starch digestion.
Mechanism of action
Hydrolysis of α-1,4 glycosidic bonds in starch
Alpha-amylase (the most common form) cleaves internal α-1,4 glycosidic bonds within amylose and amylopectin starch chains, producing maltose, maltotriose, and α-limit dextrins. The intermediate products are then further hydrolyzed by maltase, isomaltase, and sucrase enzymes in the small intestinal brush border to free glucose, which is absorbed via SGLT1 and GLUT2 transporters.
Branch-point and limit dextrin handling
Alpha-amylase cannot hydrolyze the α-1,6 branch points in amylopectin — these are handled by isomaltase. Without adequate amylase, the proportion of α-limit dextrins (containing branch points and resistant linkages) increases, potentially reaching the colon for bacterial fermentation. This is the proposed explanation for bloating after starch heavy meals in people with reduced pancreatic function; it is textbook physiology rather than something the studies cited here tested with a supplement.
Calcium-dependent activity
Alpha-amylase contains a structurally critical calcium ion in its active site. Calcium-deficient diets or calcium-binding compounds (phytates, oxalates) can theoretically reduce amylase activity. Manufacturers generally stabilize supplemental amylase to hold activity across different pH and mineral conditions, though the studies cited here did not compare products on that point.
Clinical trials
Randomized controlled trial of pancrelipase MT, a prescription pancreatic enzyme medicine, in infants and toddlers with cystic fibrosis related pancreatic insufficiency and fat malabsorption (PubMed ID 21694537). This study is linked on this page but does not appear in the reference list below.
Infants and toddlers with cystic fibrosis related pancreatic insufficiency and fat malabsorption.
The trial studied fat malabsorption in very young children with a diagnosed genetic disease, and prescription enzyme replacement is standard care for that condition. It did not measure carbohydrate digestion as a stand alone result, did not test amylase by itself, and says nothing about what a digestive enzyme supplement does for adults without pancreatic disease.
The study linked here (PubMed ID 37278449) is a 2023 observational study comparing pancreatic enzyme abnormalities and PAR-2 positive eosinophils in duodenal tissue from patients with functional dyspepsia overlapping irritable bowel syndrome. Nobody was given an enzyme product and there was no placebo group. This PubMed ID is linked on the page without appearing in the reference list.
Patients already diagnosed with functional dyspepsia overlapping irritable bowel syndrome. No intervention was given.
Because this is an observational comparison of tissue samples, it cannot show that any enzyme product relieves bloating, fullness, or post meal discomfort. It reports no symptom outcomes for a supplement of any kind.